The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -13,237,362 |
| Depreciation expense | 6,874 |
| Equity-based compensation | 1,939,896 |
| Interest receivable | -33,057 |
| Prepaid expenses | 157,883 |
| Deferred offering costs | 91,897 |
| Other assets | -1,625 |
| Accounts payable | -851,805 |
| Accrued liabilities | -244,171 |
| Net cash used in operating activities | -12,601,666 |
| Investment in property and equipment | 5,104 |
| Net cash used in investing activities | -5,104 |
| Proceeds from sale of common stock under atm | 4,861,706 |
| Issuance costs for sale of common stock under atm | 271,214 |
| Proceeds from the sale of common stock and warrants | -2,250,008 |
| Issuance costs for the sale of common stock and warrants | 291,883 |
| Proceeds from exercise of stock options | 48,000 |
| Net cash provided by financing activities | 6,596,617 |
| Net change in cash and cash equivalents | -6,010,153 |
| Cash and cash equivalents beginning of the period | 10,017,942 |
| Cash and cash equivalents end of the period | 4,007,789 |
Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. (CVKD)